22nd Century Group, Inc (NASDAQ:XXII) Stock Short Interest Report for October

22nd Century Group, Inc (NASDAQ:XXII) was the target of a large increase in short interest in October. As of October 30th, there was short interest totaling 1,198,947 shares, an increase of 3,074.8% from the October 15th total of 37,764 shares. Based on an average trading volume of 63,446,721 shares, the short-interest ratio is currently 0.0 days. Approximately 13,321.6% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 22nd Century Group in a report on Monday, October 26th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, 22nd Century Group has a consensus rating of “Sell”.

22nd Century Group Stock Down 12.9%

Shares of NASDAQ:XXII traded down $0.21 on Tuesday, hitting $1.42. The stock had a trading volume of 215,961 shares, compared to its average volume of 964,316. The firm’s 50 day moving average price is $57.49 and its 200-day moving average price is $1,877.52. The company has a quick ratio of 1.90, a current ratio of 2.61 and a debt-to-equity ratio of 0.02. 22nd Century Group has a twelve month low of $1.40 and a twelve month high of $22,446.00.

22nd Century Group (NASDAQ:XXII) last announced its earnings results on Thursday, August 13th. The biotechnology company reported ($904.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($348.00) by ($556.80). The firm had revenue of $2.86 million for the quarter, compared to analyst estimates of $7.48 million. 22nd Century Group had a negative return on equity of 69.37% and a negative net margin of 27.04%.

22nd Century Group Company Profile

22nd Century Group, Inc. was a biotechnology company focused on developing tobacco products with reduced nicotine content. Its research centered on genetically modified tobacco plants and cigarette formulations designed to lower nicotine exposure and support smoking cessation or harm-reduction efforts. The company’s principal product was VLN cigarettes, which were made with very low nicotine tobacco and marketed as containing substantially less nicotine than conventional cigarettes. 22nd Century also historically developed and commercialized other reduced-nicotine cigarette products, including Quest, and pursued applications of its plant-science technology in the tobacco and cannabinoid sectors.